David R. Patton

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

0.941Author DataRank

Indexed papers

10in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 10 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Papers

Driven by 36 papers — median percentile 0. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

1.3DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0.817DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02838

N/A

0.722DataRank · unranked

122 citations

Katherine A. Janeway, David R. Patton, Cynthia L. Winter, Brent Coffey, P. Mickey Williams +16 more

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad085

N/A

0.685DataRank · unranked

95 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0.678DataRank · unranked

91 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0.571DataRank · unranked

44 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3009

N/A

0.518DataRank · unranked

16 citations

Amit J. Sabnis, Paul M. Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10009

N/A

0.464DataRank · unranked

21 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10007

N/A

0.464DataRank · unranked

21 citations

Alexander J. Chou, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

The Oncologist(2024)10.1093/oncolo/oyae119

N/A

0.363DataRank · unranked

7 citations

AeRang Kim, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

JCO Precision Oncology(2024)10.1200/po.24.00327

N/A

0.260DataRank · unranked

4 citations

Opeyemi A. Jegede, David M. Jackman, James A. Zwiebel, Robert J. Gray, Victoria Wang +17 more

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0.241DataRank · unranked

4 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10006

N/A

0.241DataRank · unranked

4 citations

Rajen Mody, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo +14 more

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10007

N/A

0.208DataRank · unranked

3 citations

Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, P. Mickey Williams +16 more

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10008

N/A

0.165DataRank · unranked

2 citations

Olive S. Eckstein, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188

Top 78%

0.104DataRank

Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2560

Top 78%

0.104DataRank

Top 78%1 citations

Jennifer L. Silhavy, Jennifer S. LoCoco, Biswajit Das, Sorena Rahmanian, Ting-Chia Chang +15 more

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

JCO Precision Oncology(2024)10.1200/po-24-00514

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Andrew Poklepovic, Eric A. Collisson, James A. Zwiebel, Robert J. Gray +14 more

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0.104DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.2616

N/A

0DataRank · unranked

0 citations

Nilofer S. Azad, Jennifer Lee, Jacob P. K. Gross, Michael J. Overman, Katrina Kao +14 more

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V

European Journal of Cancer(2022)10.1016/s0959-8049(22)01026-7

N/A

0DataRank · unranked

3 citations

Zeyuan Song, A. Poklepovic, Eric A. Collisson, Edith P. Mitchell, James Zweibel +15 more

David R. Patton

Indexed papers

Top data-sharing exemplar

Papers